Cargando…

Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome

INTRODUCTION: In autoimmune atypical hemolytic uremic syndrome (aHUS), the complement regulator factor H (FH) is blocked by FH autoantibodies, while 90% of the patients carry a homozygous deletion of its homolog complement FH-related protein 1 (CFHR1). The functional consequence of FH-blockade is wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Trojnár, Eszter, Józsi, Mihály, Uray, Katalin, Csuka, Dorottya, Szilágyi, Ágnes, Milosevic, Danko, Stojanović, Vesna D., Spasojević, Brankica, Rusai, Krisztina, Müller, Thomas, Arbeiter, Klaus, Kelen, Kata, Szabó, Attila J., Reusz, György S., Hyvärinen, Satu, Jokiranta, T. Sakari, Prohászka, Zoltán
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371605/
https://www.ncbi.nlm.nih.gov/pubmed/28424685
http://dx.doi.org/10.3389/fimmu.2017.00302
_version_ 1782518452635828224
author Trojnár, Eszter
Józsi, Mihály
Uray, Katalin
Csuka, Dorottya
Szilágyi, Ágnes
Milosevic, Danko
Stojanović, Vesna D.
Spasojević, Brankica
Rusai, Krisztina
Müller, Thomas
Arbeiter, Klaus
Kelen, Kata
Szabó, Attila J.
Reusz, György S.
Hyvärinen, Satu
Jokiranta, T. Sakari
Prohászka, Zoltán
author_facet Trojnár, Eszter
Józsi, Mihály
Uray, Katalin
Csuka, Dorottya
Szilágyi, Ágnes
Milosevic, Danko
Stojanović, Vesna D.
Spasojević, Brankica
Rusai, Krisztina
Müller, Thomas
Arbeiter, Klaus
Kelen, Kata
Szabó, Attila J.
Reusz, György S.
Hyvärinen, Satu
Jokiranta, T. Sakari
Prohászka, Zoltán
author_sort Trojnár, Eszter
collection PubMed
description INTRODUCTION: In autoimmune atypical hemolytic uremic syndrome (aHUS), the complement regulator factor H (FH) is blocked by FH autoantibodies, while 90% of the patients carry a homozygous deletion of its homolog complement FH-related protein 1 (CFHR1). The functional consequence of FH-blockade is widely established; however, the molecular basis of autoantibody binding and the role of CFHR1 deficiency in disease pathogenesis are still unknown. We performed epitope mapping of FH to provide structural insight in the autoantibody recruitment on FH and potentially CFHR1. METHODS: Eight anti-FH positive aHUS patients were enrolled in this study. With overlapping synthetic FH and CFHR1 peptides, we located the amino acids (aa) involved in binding of acute and convalescence stage autoantibodies. We confirmed the location of the mapped epitopes using recombinant FH domains 19–20 that carried single-aa substitutions at the suspected antibody binding sites in three of our patients. Location of the linear epitopes and the introduced point mutations was visualized using crystal structures of the corresponding domains of FH and CFHR1. RESULTS: We identified three linear epitopes on FH (aa1157–1171; aa1177–1191; and aa1207–1226) and one on CFHR1 (aa276–290) that are recognized both in the acute and convalescence stages of aHUS. We observed a similar extent of autoantibody binding to the aHUS-specific epitope aa1177–1191 on FH and aa276–290 on CFHR1, despite seven of our patients being deficient for CFHR1. Epitope mapping with the domain constructs validated the location of the linear epitopes on FH with a distinct autoantibody binding motif within aa1183–1198 in line with published observations. SUMMARY: According to the results, the linear epitopes we identified are located close to each other on the crystal structure of FH domains 19–20. This tertiary configuration contains the amino acids reported to be involved in C3b and sialic acid binding on the regulator, which may explain the functional deficiency of FH in the presence of autoantibodies. The data we provide identify the exact structures involved in autoantibody recruitment on FH and confirm the presence of an autoantibody binding epitope on CFHR1.
format Online
Article
Text
id pubmed-5371605
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-53716052017-04-19 Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome Trojnár, Eszter Józsi, Mihály Uray, Katalin Csuka, Dorottya Szilágyi, Ágnes Milosevic, Danko Stojanović, Vesna D. Spasojević, Brankica Rusai, Krisztina Müller, Thomas Arbeiter, Klaus Kelen, Kata Szabó, Attila J. Reusz, György S. Hyvärinen, Satu Jokiranta, T. Sakari Prohászka, Zoltán Front Immunol Immunology INTRODUCTION: In autoimmune atypical hemolytic uremic syndrome (aHUS), the complement regulator factor H (FH) is blocked by FH autoantibodies, while 90% of the patients carry a homozygous deletion of its homolog complement FH-related protein 1 (CFHR1). The functional consequence of FH-blockade is widely established; however, the molecular basis of autoantibody binding and the role of CFHR1 deficiency in disease pathogenesis are still unknown. We performed epitope mapping of FH to provide structural insight in the autoantibody recruitment on FH and potentially CFHR1. METHODS: Eight anti-FH positive aHUS patients were enrolled in this study. With overlapping synthetic FH and CFHR1 peptides, we located the amino acids (aa) involved in binding of acute and convalescence stage autoantibodies. We confirmed the location of the mapped epitopes using recombinant FH domains 19–20 that carried single-aa substitutions at the suspected antibody binding sites in three of our patients. Location of the linear epitopes and the introduced point mutations was visualized using crystal structures of the corresponding domains of FH and CFHR1. RESULTS: We identified three linear epitopes on FH (aa1157–1171; aa1177–1191; and aa1207–1226) and one on CFHR1 (aa276–290) that are recognized both in the acute and convalescence stages of aHUS. We observed a similar extent of autoantibody binding to the aHUS-specific epitope aa1177–1191 on FH and aa276–290 on CFHR1, despite seven of our patients being deficient for CFHR1. Epitope mapping with the domain constructs validated the location of the linear epitopes on FH with a distinct autoantibody binding motif within aa1183–1198 in line with published observations. SUMMARY: According to the results, the linear epitopes we identified are located close to each other on the crystal structure of FH domains 19–20. This tertiary configuration contains the amino acids reported to be involved in C3b and sialic acid binding on the regulator, which may explain the functional deficiency of FH in the presence of autoantibodies. The data we provide identify the exact structures involved in autoantibody recruitment on FH and confirm the presence of an autoantibody binding epitope on CFHR1. Frontiers Media S.A. 2017-03-30 /pmc/articles/PMC5371605/ /pubmed/28424685 http://dx.doi.org/10.3389/fimmu.2017.00302 Text en Copyright © 2017 Trojnár, Józsi, Uray, Csuka, Szilágyi, Milosevic, Stojanović, Spasojević, Rusai, Müller, Arbeiter, Kelen, Szabó, Reusz, Hyvärinen, Jokiranta and Prohászka. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Trojnár, Eszter
Józsi, Mihály
Uray, Katalin
Csuka, Dorottya
Szilágyi, Ágnes
Milosevic, Danko
Stojanović, Vesna D.
Spasojević, Brankica
Rusai, Krisztina
Müller, Thomas
Arbeiter, Klaus
Kelen, Kata
Szabó, Attila J.
Reusz, György S.
Hyvärinen, Satu
Jokiranta, T. Sakari
Prohászka, Zoltán
Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome
title Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome
title_full Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome
title_fullStr Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome
title_full_unstemmed Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome
title_short Analysis of Linear Antibody Epitopes on Factor H and CFHR1 Using Sera of Patients with Autoimmune Atypical Hemolytic Uremic Syndrome
title_sort analysis of linear antibody epitopes on factor h and cfhr1 using sera of patients with autoimmune atypical hemolytic uremic syndrome
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5371605/
https://www.ncbi.nlm.nih.gov/pubmed/28424685
http://dx.doi.org/10.3389/fimmu.2017.00302
work_keys_str_mv AT trojnareszter analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome
AT jozsimihaly analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome
AT uraykatalin analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome
AT csukadorottya analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome
AT szilagyiagnes analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome
AT milosevicdanko analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome
AT stojanovicvesnad analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome
AT spasojevicbrankica analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome
AT rusaikrisztina analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome
AT mullerthomas analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome
AT arbeiterklaus analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome
AT kelenkata analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome
AT szaboattilaj analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome
AT reuszgyorgys analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome
AT hyvarinensatu analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome
AT jokirantatsakari analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome
AT prohaszkazoltan analysisoflinearantibodyepitopesonfactorhandcfhr1usingseraofpatientswithautoimmuneatypicalhemolyticuremicsyndrome